Germany’s Stada Arzneimittel AG said Monday it would support a joint takeover offer by private-equity firms Bain Capital LLC and Cinven Group Ltd. that values the drugmaker at more than $4 billion.
Bain and Cinven are offering 66 euros ($69.90) a share for Stada as well as a dividend of EUR0.72, Stada said. The bid is markedly higher than Cinven’s earlier proposal to pay EUR56 a share.
Stada received two takeover offer after a structured bidding process. The company said its executive and supervisory board decided it was in the best interest of the company to support the offer by Bain and Cinven.
“Bain Capital and Cinven have presented the most financially appealing offer,” said Stada.
The pharmaceutical company said it had signed an investor agreement with Bain and Cinven that has “extensive protection provisions” for employees, production sites and the corporate strategy. Stada’s executive and supervisory boards will review the offer document upon its release, the company said.
“From today’s vantage point, both boards expect to be able to recommend the offer for acceptance to the shareholders,” said Stada.
By Friedrich Geiger
Source: MarketWatch
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
